Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

By The Northwire Desk — AI Analysis Jan 13, 2026 · 08:00 LABS · 0.075 MEDIPHARM LABS CORP. J
LABS · Price

Executive Summary

  • MediPharm Labs Corp. has signed a definitive supply agreement with Remidose Aerosols Inc. to provide GMP‑certified medicinal cannabis products to Costa Rica through Remidose LATAM SRL.
  • The partnership targets the newly opened Costa Rican medical cannabis market, projected to exceed US$35 million annually.
  • Shipments will include oils, tinctures, metered‑dose inhalers and dried flower once remaining regulatory requirements are satisfied.

Key Details

  • Parties: MediPharm Labs Corp. (TSX: LABS) and Remidose Aerosols Inc., with shipments to Remidose LATAM SRL.
  • Products Covered: GMP‑certified cannabis oils, tinctures, metered‑dose inhalers, and dried flower.
  • Market Context: Costa Rica’s regulated medical cannabis market launched in June 2025; forecasted annual sales > US$35 million (6Wresearch).
  • Regulatory Status: Remidose LATAM is fully licensed by Costa Rican health authorities; final import approvals pending completion of remaining requirements.
  • Commercial Impact: Expands MediPharm’s international footprint and leverages its GMP manufacturing capability to enter a high‑growth, regulated market.
  • CEO Quote (David Pidduck): Highlights MediPharm’s ability to navigate complex regulations and deliver high‑quality products globally.
  • President Quote (Michael Mayne – Remidose): Emphasizes the partnership’s role in providing patients with top‑tier GMP cannabis solutions.

Notable Quotes

“MediPharm Labs’ proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannabinoid products to highly regulated markets worldwide.” – David Pidduck, CEO, MediPharm Labs

“Remidose LATAM is proud to be fully licensed and authorized by Costa Rican health authorities…Partnering with MediPharm Labs allows us to offer patients access to some of the highest quality, GMP‑certified cannabis products available globally.” – Michael Mayne, President, Remidose

Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Apr 27, 2026 · 08:30

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

Regulatory Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management